Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
February 27, 2025 16:15 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced a collaboration with Gabbi to provide an integrated offering for breast cancer risk assessment.
Myriad Genetics Announces Senior Leadership Transition
February 24, 2025 16:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics announces senior leadership transition; Sam Raha as CEO and Mark S. Verratti as COO effective April 30, 2025.
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
February 24, 2025 16:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics today announced financial results for its fourth quarter and full-year ended December 31, 2024.
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
February 24, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
February 19, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics has been named on the Forbes list of America’s Best Employers 2025.
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
February 18, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025.
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
February 06, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics and CancerCARE for Life announced an agreement designed to enhance education and access to hereditary cancer testing.
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
February 05, 2025 16:15 ET
|
Myriad Genetics, Inc.
Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay.
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
February 05, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
January 29, 2025 08:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics will unveil groundbreaking eight weeks’ gestation NIPT study results at the annual SMFM conference.